NCT02726659

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression: a Randomized, Double-blind, Placebo-controlled Trial

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The investigators will conduct a 6-week, randomized, double-blind, placebo-controlled trial of celecoxib as an add-on treatment to the mood stabilizer among women with bipolar I or II postpartum depression. Women who are taking a mood stabilizer for treatment of bipolar disorder in the postpartum treatment will receive either a placebo or celecoxib add-on treatment. Patients will be monitored regularly to assess psychiatric symptoms and side effects. The investigators aim to evaluate the potential antidepressant effect of celecoxib in bipolar postpartum depression.

Conditions

• Bipolar Disorder
• Postpartum Depression

Interventions

Type	Name	Description
DRUG	Celecoxib	Adjunct celecoxib
DRUG	Placebo	Adjunct placebo

Timeline

• Start date: 2016-05-01
• Primary completion: 2019-01-16
• Completion: 2019-01-16
• First posted: 2016-04-04
• Last updated: 2022-01-20

Locations

1 site across 1 country: Canada